Myeloma Care: Quad Therapies, Bispecifics, and the Role of Oncology Nurses

The multiple myeloma treatment landscape is shifting rapidly, driven by the emergence of novel immunotherapies and highly effective multi-drug combinations. Navigating these changes in a clinical setting requires close coordination across the oncology care team. Following a recent Oncology Nursing News case-based roundtable discussion, Melissa LaMirand, MSN, RN, FNP-C, a multiple myeloma nurse practitioner at the Duke University Blood Cancer Center, highlighted key clinical strategies for standardizing care, managing treatment-associated toxicities, and navigating frontline therapy options.

LaMirand, whose background in bone marrow transplant and blood cancer care extends back to 2009, emphasized that peer-to-peer alignment is essential for clinical success and patient safety.

Bridging the Provider-Nurse Communication Gap

Peer-to-peer educational events are vital for aligning outpatient advanced practice providers with the clinical nursing staff who physically administer therapies. Roundtable discussions reveal that operational gaps can occur even within the same clinic.

• Aligning Administration Practices: Roundtable exchanges help reveal discrepancies between how providers believe monoclonal antibodies are given versus actual clinic administration workflows.
• Informing Patient Education: Gaining direct insight into clinical nursing practices enables outpatient providers to educate and counsel patients more effectively.
• Explaining the "Why": Clinic nurses benefit from understanding the provider’s clinical rationale behind regimen selection and therapeutic backbones.
• Ensuring Continuity: Ongoing standardization keeps both provider and nursing entities on the same page, keeping the patient at the center of care and improving long-term outcomes.

Frontline Quadruplet Regimens and Sequencing Challenges

The rapid adoption of anti-CD38 monoclonal antibody-based quadruplet therapies is redefining frontline treatment standards for newly diagnosed patients.

• Aggressive Early Intervention: Frontline quadruplet regimens utilizing monoclonal antibodies are rapidly shifting into the early-line setting, establishing a robust new standard.
• The Sequencing Dilemma: Choosing highly effective upfront therapy creates a "muddy" and "tricky" landscape for sequencing subsequent therapies upon relapse. Providers must select regimens that maximize immediate progression-free survival (PFS) without inadvertently excluding future therapeutic options, particularly for younger patients who need to live a long life.
• A Focus on High-Risk Populations: With refined definitions of high-risk and ultra-high-risk myeloma, monoclonal antibodies play an increasingly critical role upfront, maximizing PFS while preserving quality of life.

Expanding Access to Bispecific Antibodies in the Community

While bispecific antibodies (bites) deliver unprecedented response rates, their associated step-up dosing and risks of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) often restrict delivery to academic settings.

• Leveraging Academic Infrastructure: Academic institutions possess the specialized pathways, workflows, and clinical infrastructure necessary to manage complex, high-risk patients undergoing immunotherapy.
• Bridging the Academic-Community Gap: Academic centers can partner with community oncology practices to help them establish the pathways and workflows required to manage these agents locally.
• Selecting Low-Risk Patients: Standard-risk patients with few comorbidities are excellent candidates for community-based bispecific therapy.
• Proactive Planning: Establishing workflows and pathways before they are needed is key; clinics must remember that while CRS requires vigilance, severe outcomes are rare, and "nobody dies from grade 1 CRS."

Managing Cumulative Immunosuppression

As highly active immunotherapies are administered over extended periods, managing cumulative immunosuppression has become a clinical responsibility for oncology nurses.

• Prophylactic Antibiotics: High-risk patients with a history of recurrent infections or pneumonia should receive prophylactic antibiotics.
• Monthly IVIG Therapy: Administering intravenous immunoglobulin (IVIG) monthly, regardless of baseline IgG levels, has proven highly effective in preventing respiratory infections and keeping patients on treatment longer.
• Insurance Barriers: Navigating insurance approvals for off-guideline IVIG use remains a common practical hurdle for nursing teams.

Re-evaluating Autologous Stem Cell Transplantation

The rise of highly effective quad regimens, CAR T-cell therapies, and bispecifics has challenged the historic role of autologous stem cell transplantation (ASCT).

• An Evolving Paradigm: Autologous transplant may soon become a thing of the past as newer cellular therapies take its place.
• Comparable Efficacy, Lower Toxicity: CAR-T therapies yield similar outcomes to ASCT with lower overall toxicity, while bispecifics offer highly effective alternatives for frail patients.
• Collection and Storage Conversations: Providers and nurses must refer patients to academic or transplant facilities early. This allows patients to discuss the merits of immediate ASCT versus stem cell collection and storage for later use.

Caregiver Education in Outpatient Cellular Therapy

As cellular therapies transition to outpatient settings, thorough caregiver education is essential for patient safety.

• The Caregiver Mandate: Outpatient cellular therapy cannot succeed without a reliable caregiver who can identify subtle physical and cognitive changes.
• Home Monitoring: Caregivers must be trained to monitor vital signs daily, watching for fevers and changes in heart rate.
• Neurological Warning Signs: Key symptoms requiring immediate clinical contact include fever, altered speech, confusion, or persistent headaches.
• Accessible Points of Contact: Caregivers must have immediate access to emergency clinical phone numbers, ideally posted on the refrigerator or kept in a wallet.